These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 16772624)

  • 21. n-3 Fatty acids, cardiac arrhythmia and fatal coronary heart disease.
    Brouwer IA; Geelen A; Katan MB
    Prog Lipid Res; 2006 Jul; 45(4):357-67. PubMed ID: 16678270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
    Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
    J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients.
    Wilkoff BL; Hess M; Young J; Abraham WT
    J Cardiovasc Electrophysiol; 2004 Sep; 15(9):1002-9. PubMed ID: 15363071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms in the GNAS Gene as Predictors of Ventricular Tachyarrhythmias and Sudden Cardiac Death: Results From the DISCOVERY Trial and Oregon Sudden Unexpected Death Study.
    Wieneke H; Svendsen JH; Lande J; Spencker S; Martinez JG; Strohmer B; Toivonen L; Le Marec H; Garcia-Fernandez FJ; Corrado D; Huertas-Vazquez A; Uy-Evanado A; Rusinaru C; Reinier K; Foldesi C; Hulak W; Chugh SS; Siffert W
    J Am Heart Assoc; 2016 Nov; 5(12):. PubMed ID: 27895044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
    Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
    Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial.
    Finzi AA; Latini R; Barlera S; Rossi MG; Ruggeri A; Mezzani A; Favero C; Franzosi MG; Serra D; Lucci D; Bianchini F; Bernasconi R; Maggioni AP; Nicolosi G; Porcu M; Tognoni G; Tavazzi L; Marchioli R
    Am Heart J; 2011 Feb; 161(2):338-343.e1. PubMed ID: 21315217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial.
    Wilkoff BL; Ousdigian KT; Sterns LD; Wang ZJ; Wilson RD; Morgan JM;
    J Am Coll Cardiol; 2006 Jul; 48(2):330-9. PubMed ID: 16843184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
    Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.
    Ruwald MH; Solomon SD; Foster E; Kutyifa V; Ruwald AC; Sherazi S; McNitt S; Jons C; Moss AJ; Zareba W
    Circulation; 2014 Dec; 130(25):2278-86. PubMed ID: 25301831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. n-3 Fatty acids and ventricular arrhythmias in patients with ischaemic heart disease and implantable cardioverter defibrillators.
    Christensen JH; Riahi S; Schmidt EB; Mølgaard H; Kirstein Pedersen A; Heath F; Cosedis Nielsen J; Toft E
    Europace; 2005 Jul; 7(4):338-44. PubMed ID: 15944091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators.
    Lampert R; McPherson CA; Clancy JF; Caulin-Glaser TL; Rosenfeld LE; Batsford WP
    J Am Coll Cardiol; 2004 Jun; 43(12):2293-9. PubMed ID: 15193696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial.
    Thies F; Garry JM; Yaqoob P; Rerkasem K; Williams J; Shearman CP; Gallagher PJ; Calder PC; Grimble RF
    Lancet; 2003 Feb; 361(9356):477-85. PubMed ID: 12583947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
    Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
    Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
    Connolly SJ; Dorian P; Roberts RS; Gent M; Bailin S; Fain ES; Thorpe K; Champagne J; Talajic M; Coutu B; Gronefeld GC; Hohnloser SH;
    JAMA; 2006 Jan; 295(2):165-71. PubMed ID: 16403928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of fish oil in arrhythmia prevention.
    Anand RG; Alkadri M; Lavie CJ; Milani RV
    J Cardiopulm Rehabil Prev; 2008; 28(2):92-8. PubMed ID: 18360184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial.
    Kowey PR; Reiffel JA; Ellenbogen KA; Naccarelli GV; Pratt CM
    JAMA; 2010 Dec; 304(21):2363-72. PubMed ID: 21078810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention.
    Mehta RH; Starr AZ; Lopes RD; Hochman JS; Widimsky P; Pieper KS; Armstrong PW; Granger CB;
    JAMA; 2009 May; 301(17):1779-89. PubMed ID: 19417195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immediate effects of n-3 fatty acid infusion on the induction of sustained ventricular tachycardia.
    Schrepf R; Limmert T; Claus Weber P; Theisen K; Sellmayer A
    Lancet; 2004 May; 363(9419):1441-2. PubMed ID: 15121409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.
    Moss AJ; Greenberg H; Case RB; Zareba W; Hall WJ; Brown MW; Daubert JP; McNitt S; Andrews ML; Elkin AD;
    Circulation; 2004 Dec; 110(25):3760-5. PubMed ID: 15583079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.